Indaptus Therapeutics Inc (INDP) Stock Price, Quote & News

Company Profile

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The com...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 427 2727

Website: indaptusrx.com

Address:

Three Columbus Circle, 15th Floor, New York, United States

AutoAZTrader May. 15 at 11:57 PM

$INDP Fuck you shorts; hope you die in hell.

0 · Reply

TwongStocks May. 15 at 12:28 PM

$INDP Here's the 10-Q https://www.sec.gov/ix?doc=/Archives/edgar/data/1857044/000149315226023362/form10-q.htm • Cash fell from $8.5M on Dec 31 to $1.5M on Mar 31 primarily from payment of accounts payable and other current liabilities. • Confirmed that as of Apr 16, Michal Newman resigned as Chief Scientific Officer.

0 · Reply

TwongStocks May. 15 at 11:09 AM

$INDP Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update https://www.globenewswire.com/news-release/2026/05/15/3295732/0/en/indaptus-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update.html New CEO Junyi Dai reiterates that they "remain focused on supporting and advancing its therapeutic and research activities." As part of their evaluation of Decoy, they are reassessing the Company’s development priorities, operating initiatives, and resource allocation (see screenshots). • Confirms all outstanding Series AA and Series AAA preferred shares were converted. • 113,242,324 shares outstanding as of March 31 (after conversion of preferred shares) • $1.5M cash on hand as of March 31

1 · Reply

iTradeHalfAsleep May. 8 at 11:06 AM

$INDP 🌚

0 · Reply

wjmax May. 5 at 5:27 PM

$INDP Is the website down?

3 · Reply

aztecb May. 5 at 9:35 AM

$INDP it seems active this morning, i hope this is a sign we have a good day.

0 · Reply

888ixo May. 4 at 10:36 PM

$INDP 🧙

0 · Reply

OfficialStocktwitsUser May. 4 at 2:24 PM

$INDP RSI: 49.57, MACD: 0.1705 Vol: 0.68, MA20: 2.73, MA50: 2.20 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

daybaron May. 1 at 8:47 PM

$INDP wow that is disappointing, thought we were on to something last couple weeks

0 · Reply

AutoAZTrader Apr. 29 at 7:37 PM

$INDP Oh, great some fucking volume. Off the fuckimng cliff. What a fucking piece of shit. Why is this allowed in the market? Worthless.

0 · Reply

Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

2025-12-29T12:05:06.000Z - 5 months ago

Indaptus Therapeutics enters $6M securities purchase agreement with David Lazar

Dec 29, 2025, 7:00 AM EST - 5 months ago

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Nov 17, 2025, 8:00 AM EST - 6 months ago

Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

2025-11-12T13:35:39.000Z - 6 months ago

Indaptus Therapeutics reports Q3 EPS ($2.98) vs ($9.04) last year

Nov 12, 2025, 8:30 AM EST - 6 months ago

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

2025-09-04T20:05:09.000Z - 9 months ago

Indaptus Therapeutics provides update on INDP-D101 clinical trial

Sep 4, 2025, 4:01 PM EDT - 9 months ago

Indaptus Therapeutics Provides Clinical Update

Sep 2, 2025, 4:05 PM EDT - 9 months ago

Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference

2025-09-02T13:20:12.000Z - 9 months ago

Indaptus Therapeutics files to sell 781,250 shares of common stock, warrants

2025-08-13T20:26:36.000Z - 9 months ago

Indaptus Therapeutics files $200M mixed securities shelf

2025-08-13T20:25:40.000Z - 9 months ago

Indaptus Therapeutics files to sell 2.16M shares of common stock for holders

2025-08-13T12:16:03.000Z - 9 months ago

Indaptus Therapeutics reports Q2 EPS ($9.09) vs ($13.16) last year

Aug 13, 2025, 8:00 AM EDT - 9 months ago

Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2025-07-01T12:21:19.000Z - 11 months ago

Indaptus Therapeutics announces additional sale of $3.4M in private placement

Jul 1, 2025, 8:14 AM EDT - 11 months ago

Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants

2025-06-27T14:10:13.000Z - 11 months ago

Indaptus Therapeutics Inc trading resumes

2025-06-27T14:05:34.000Z - 11 months ago

Indaptus Therapeutics Inc trading halted, volatility trading pause

2025-06-26T23:50:25.000Z - 11 months ago

Indaptus Therapeutics Inc trading halted, news pending

2025-06-25T11:21:40.000Z - 11 months ago

Indaptus Therapeutics board approves 1-for-28 reverse stock split

Jun 25, 2025, 7:00 AM EDT - 11 months ago

Indaptus Therapeutics Announces Reverse Stock Split

2025-06-13T12:16:00.000Z - 1 year ago

Indaptus Therapeutics announces sale of $2.3M of convertible notes, warrants

Jun 13, 2025, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

2025-06-02T12:21:33.000Z - 1 year ago

Indaptus doses first patient in Phase 1b.2 study of Decoy20 withTislelizumab

ONC

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

2025-05-14T12:35:54.000Z - 1 year ago

Indaptus Therapeutics reports Q1 EPS (32c) vs. (45c) last year

May 14, 2025, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

2025-03-20T12:11:35.000Z - 1 year ago

Indaptus Therapeutics reports new data on Phase 1 trial of Decoy20

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

2025-03-18T12:20:25.000Z - 1 year ago

Indaptus Therapeutics initiates Phase 1 study of Decoy20

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

2025-03-13T11:37:24.000Z - 1 year ago

Indaptus Therapeutics reports FY24 EPS ($1.61) vs ($1.83) last year

Mar 13, 2025, 7:30 AM EDT - 1 year ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 4:15 PM EDT - 1 year ago

Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

Mar 4, 2025, 8:00 AM EST - 1 year ago

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Feb 25, 2025, 8:00 AM EST - 1 year ago

Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Feb 5, 2025, 8:00 AM EST - 1 year ago

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Jan 8, 2025, 8:00 AM EST - 1 year ago

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Nov 22, 2024, 8:36 AM EST - 1 year ago

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Nov 11, 2024, 8:00 AM EST - 1 year ago

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Nov 7, 2024, 8:00 AM EST - 1 year ago

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

May 8, 2024, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 11, 2024, 7:30 AM EDT - 2 years ago

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Mar 25, 2024, 8:30 AM EDT - 2 years ago

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Mar 13, 2024, 7:30 AM EDT - 2 years ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 4, 2024, 7:30 AM EST - 2 years ago

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

Feb 8, 2024, 8:00 AM EST - 2 years ago

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

Jan 4, 2024, 8:00 AM EST - 2 years ago

European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology

Nov 6, 2023, 4:01 PM EST - 2 years ago

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 31, 2023, 9:01 AM EDT - 2 years ago

Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Registration Is Now Open For Tribe Public's Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics' CEO On Friday, September 29, 2023

Sep 6, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 3 years ago

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 8:45 AM EDT - 3 years ago

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Aug 7, 2023, 8:00 AM EDT - 3 years ago

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

May 11, 2023, 7:00 AM EDT - 3 years ago

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 8:00 AM EDT - 3 years ago

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

May 1, 2023, 8:00 AM EDT - 3 years ago

Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

Apr 20, 2023, 4:05 PM EDT - 3 years ago

Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

Apr 19, 2023, 9:28 AM EDT - 3 years ago

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Apr 19, 2023, 8:05 AM EDT - 3 years ago

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Indaptus Therapeutics to Present at the Investor Summit Conference

Mar 17, 2023, 8:00 AM EDT - 3 years ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Mar 15, 2023, 8:05 AM EDT - 3 years ago

Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023

Mar 13, 2023, 8:05 AM EDT - 3 years ago

Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

AutoAZTrader May. 15 at 11:57 PM

$INDP Fuck you shorts; hope you die in hell.

0 · Reply

TwongStocks May. 15 at 12:28 PM

0 · Reply

TwongStocks May. 15 at 11:09 AM

1 · Reply

iTradeHalfAsleep May. 8 at 11:06 AM

$INDP 🌚

0 · Reply

wjmax May. 5 at 5:27 PM

$INDP Is the website down?

3 · Reply

aztecb May. 5 at 9:35 AM

$INDP it seems active this morning, i hope this is a sign we have a good day.

0 · Reply

888ixo May. 4 at 10:36 PM

$INDP 🧙

0 · Reply

OfficialStocktwitsUser May. 4 at 2:24 PM

0 · Reply

daybaron May. 1 at 8:47 PM

$INDP wow that is disappointing, thought we were on to something last couple weeks

0 · Reply

AutoAZTrader Apr. 29 at 7:37 PM

$INDP Oh, great some fucking volume. Off the fuckimng cliff. What a fucking piece of shit. Why is this allowed in the market? Worthless.

0 · Reply

AutoAZTrader Apr. 29 at 7:28 PM

$INDP Not a single trade in an hour; we are fucked.

0 · Reply

AutoAZTrader Apr. 29 at 5:28 PM

$INDP No volume at all. Pathetic.

0 · Reply

focafoca99 Apr. 25 at 5:58 AM

$INDP named new independent directors effective April 22. https://www.rapidticker.com/news/indp-sec-filing-1ef8d7

0 · Reply

RedDogSailor Apr. 23 at 6:39 PM

$INDP So what’s the plan with the new owners? Are they going to pursue the tech or do a reverse merger.

1 · Reply

TwongStocks Apr. 22 at 8:21 PM

$INDP Former CEO's farewell message on LinkedIn "After careful consideration, we made the difficult decision to pursue a transaction last year that represents the most responsible outcome for our shareholders under the circumstances." ... "The challenge we ultimately faced was not the science. It was scale. Advancing this approach through the trials required for approval would likely demand $50–100 + million. Given our market capitalization and the reality of raising capital for small biotechs over the last few years, continuing independently just simply wasn’t feasible."

1 · Reply